These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7655826)

  • 21. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells.
    Jilek S; Merkle HP; Walter E
    Adv Drug Deliv Rev; 2005 Jan; 57(3):377-90. PubMed ID: 15560947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines.
    Waeckerle-Men Y; Groettrup M
    Adv Drug Deliv Rev; 2005 Jan; 57(3):475-82. PubMed ID: 15560953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microparticles for the delivery of DNA vaccines.
    O'Hagan DT; Singh M; Ulmer JB
    Immunol Rev; 2004 Jun; 199():191-200. PubMed ID: 15233735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
    Jaganathan KS; Vyas SP
    Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices.
    Jain RA
    Biomaterials; 2000 Dec; 21(23):2475-90. PubMed ID: 11055295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biodegradable polymeric microparticles for drug delivery and vaccine formulation: the surface attachment of hydrophilic species using the concept of poly(ethylene glycol) anchoring segments.
    Coombes AG; Tasker S; Lindblad M; Holmgren J; Hoste K; Toncheva V; Schacht E; Davies MC; Illum L; Davis SS
    Biomaterials; 1997 Sep; 18(17):1153-61. PubMed ID: 9259512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems.
    Delgado A; Lavelle EC; Hartshorne M; Davis SS
    Vaccine; 1999 Jul; 17(22):2927-38. PubMed ID: 10438065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poly D,L-lactide-co-glycolic acid (PLGA)-encapsulated vaccine on immune system in Epinephelus bruneus against Uronema marinum.
    Harikrishnan R; Balasundaram C; Heo MS
    Exp Parasitol; 2012 Jul; 131(3):325-32. PubMed ID: 22580022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biodegradable microparticles as oral vaccines.
    O'Hagan DT; Jeffery H; Maloy KJ; Mowat AM; Rahman D; Challacombe SJ
    Adv Exp Med Biol; 1995; 371B():1463-7. PubMed ID: 7502838
    [No Abstract]   [Full Text] [Related]  

  • 30. Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery.
    Pavot V; Berthet M; Rességuier J; Legaz S; Handké N; Gilbert SC; Paul S; Verrier B
    Nanomedicine (Lond); 2014 Dec; 9(17):2703-18. PubMed ID: 25529572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on the potential of microparticles entrapping pDNA-poly(aminoacids) complexes as vaccine delivery systems.
    Benoit MA; Ribet C; Distexhe J; Hermand D; Letesson JJ; Vandenhaute J; Gillard J
    J Drug Target; 2001; 9(4):253-66. PubMed ID: 11697029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controlled release microparticles for vaccine development.
    O'Hagan DT; Jeffery H; Roberts MJ; McGee JP; Davis SS
    Vaccine; 1991 Oct; 9(10):768-71. PubMed ID: 1759495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poly-D,L-lactide-co-poly(ethylene glycol) microspheres as potential vaccine delivery systems.
    Zhou S; Liao X; Li X; Deng X; Li H
    J Control Release; 2003 Jan; 86(2-3):195-205. PubMed ID: 12526816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D,L-lactide-co-glycolide) microspheres.
    Allaoui-Attarki K; Fattal E; Pecquet S; Trollé S; Chachaty E; Couvreur P; Andremont A
    Vaccine; 1998 Apr; 16(7):685-91. PubMed ID: 9562687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system.
    Lima KM; Rodrigues Júnior JM
    Braz J Med Biol Res; 1999 Feb; 32(2):171-80. PubMed ID: 10347752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches.
    Jain R; Shah NH; Malick AW; Rhodes CT
    Drug Dev Ind Pharm; 1998 Aug; 24(8):703-27. PubMed ID: 9876519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biodegradable poly(DL-lactide-co-glycolide) microspheres.
    Eldridge JH; Staas JK; Tice TR; Gilley RM
    Res Immunol; 1992 Jun; 143(5):557-63; discussion 581. PubMed ID: 1439138
    [No Abstract]   [Full Text] [Related]  

  • 38. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination.
    Johansen P; Men Y; Merkle HP; Gander B
    Eur J Pharm Biopharm; 2000 Jul; 50(1):129-46. PubMed ID: 10840197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery.
    Davis SS
    Vaccine; 2006 Apr; 24 Suppl 2():S2-7-10. PubMed ID: 16823907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Charged polylactide co-glycolide microparticles as antigen delivery systems.
    Singh M; Kazzaz J; Ugozzoli M; Chesko J; O'Hagan DT
    Expert Opin Biol Ther; 2004 Apr; 4(4):483-91. PubMed ID: 15102598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.